New glaucoma progression predictors

Article

Lower systolic perfusion pressure, lower systolic blood pressure and cardiovascular disease history are all predictors of glaucoma.

Lower systolic perfusion pressure, lower systolic blood pressure and cardiovascular disease history are all predictors of glaucoma, according to a study published online ahead of print by Ophthalmology.

Researchers from the Early Manifest Glaucoma Trial (EMGT) examined the progression criteria of patients with early open-angle glaucoma (OAG). A total of 255 patients with OAG were randomized to be treated with argon laser trabeculoplasty plus betaxolol (n=129) or to receive no immediate treatment (n=126). Subjects were examined every three months for up to 11 years in some cases.

The researchers discovered that lower systolic perfusion pressure, lower systolic blood pressure and cardiovascular disease history are all predictors of glaucoma, suggesting a vascular role in glaucoma progression. Another new factor discovered was thinner central corneal thickness (CCT), with results suggesting a preferential CCT effect with higher IOP.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.